NCT01638325

A Study of Insulin Lispro With BioChaperone Excipient in Healthy Participants

A Study to Assess the Pharmacokinetics, Glucodynamics, Safety, and Tolerability of Single Subcutaneous Injections of Insulin Lispro With BioChaperone Excipient in Healthy Volunteers

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 37 (actual)
• Sponsor: Adocia · Industry
• Sex: All
• Age: 21 Years – 65 Years
• Healthy volunteers: Accepted

Summary

BC106 is a molecule that when injected with insulin lispro may change the speed of absorption of insulin lispro. The purpose of this study will be to evaluate the safety of BC106 insulin lispro and any side effects that might be associated with it, blood levels of insulin lispro after injection under the skin and how BC106 insulin lispro affects blood sugar after injection under the skin. There is a minimum 7 day washout between single doses.

Conditions

• Healthy Participants

Interventions

Type	Name	Description
DRUG	Insulin Lispro	Administered SC
DRUG	BC106 insulin lispro	Administered SC

Timeline

• Start date: 2012-07-01
• Primary completion: 2012-09-01
• Completion: 2012-09-01
• First posted: 2012-07-11
• Last updated: 2014-06-16

Locations

1 site across 1 country: Singapore